sglt2 inhibitors and glp-1 receptor agonists together Complementary Yet Distinct Roles of in Cardiovascular Risk Reduction Illustration of potential synergistic effects

Most intestinal K cells secrete a biologically active form of GIP consisting of 42 amino acids, GIP (42), which is derived from a 153 amino acid preprohormone precursor distinct from preproglucagon ( Figure 2 ]

However, this study has some limitations

Hamal S, Cherukuri L, Shaikh K, Kinninger A, Doshi J, Birudaraju D, et al

doi: 10.1016/j.ejphar.2017.06.029 [DOI] [PubMed] [Google Scholar] 112.Feng P, Zhang X, Li D, Ji C, Yuan Z, Wang R, et al

In obese mice, the GIPR/GLP-1R co-agonist produced greater decreases in body weight and food intake, as well as improved glycemic and lipid outcomes, when compared to equal doses of either exendin-4 or liraglutide

TRIPLE GLUCAGON-LIKE PEPTIDE-1/GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE/GLUCAGON RECEPTOR TRIAGONISTS Undoubtedly, the approval of the first GLP-1 receptor agonist in 2005 has revolutionised the pharmacological treatment of obesity and T2DM